SNTI
Senti Biosciences, Inc. NASDAQ Listed May 26, 2021$0.43
-4.23%
vs $0.45
Mkt Cap $96.7M
52w Low $0.34
4.4% of range
52w High $2.39
50d MA $0.71
200d MA $1.07
P/E (TTM)
-0.2x
EV/EBITDA
—
P/B
17.3x
Debt/Equity
5.2x
ROE
-1099.3%
P/FCF
-2.2x
RSI (14)
59.10
ATR (14)
$0.04
Beta
2.12
50d MA
$0.71
200d MA
$1.07
Avg Volume
327.1K
Senti Biosciences, Inc. operates as a gene circuit company. The company develops cell and gene therapies engineered with gene circuits that are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to respective cellular environments. Its synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells to target particularly challenging liquid and solid tumor oncology indications. The company's lead programs include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells, while sparing the healthy bone marrow; and SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma (HCC). It also develops SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer (CRC) cells, while sparing healthy cells in the body. The company was founded in 2016 and is based in South San Francisco, California.
2 Corporate Drive · South San Francisco, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 27, 2026 | AMC | -0.43 | -0.38 | +11.6% | 0.79 | -1.3% | -2.3% | +5.2% | +3.3% | +2.1% | +6.5% | — |
| Nov 13, 2025 | AMC | -0.59 | -0.69 | -16.9% | 1.79 | -2.8% | -10.1% | -9.9% | +17.9% | +2.9% | +2.8% | — |
| Aug 7, 2025 | AMC | -0.90 | -0.56 | +37.8% | 1.54 | +1.9% | +2.6% | -3.8% | -2.6% | +4.1% | -0.6% | — |
| May 6, 2025 | AMC | -0.58 | -1.41 | -143.1% | 3.30 | -3.3% | +0.6% | -0.3% | -1.5% | +0.0% | -4.9% | — |
| Mar 20, 2025 | AMC | -3.13 | -0.67 | +78.6% | 3.51 | +5.4% | +4.8% | +1.1% | -4.8% | +0.3% | -6.2% | — |
| Nov 14, 2024 | AMC | — | -6.31 | — | 2.33 | +6.0% | -7.7% | -2.8% | +4.3% | -2.8% | +0.0% | — |
| Aug 13, 2024 | AMC | — | -2.45 | — | 1.97 | +1.0% | +10.2% | +5.5% | +0.9% | -8.7% | -0.9% | — |
| May 9, 2024 | AMC | — | -2.60 | — | 3.70 | +0.8% | -0.3% | -1.9% | +3.9% | +0.5% | +0.5% | — |
| Mar 21, 2024 | AMC | -0.23 | -4.20 | -1726.1% | 4.70 | -4.5% | -6.6% | -7.1% | +1.0% | -5.3% | -3.3% | — |
| Nov 13, 2023 | AMC | -4.80 | -2.50 | +47.9% | 4.34 | -10.1% | -19.4% | +6.3% | +4.6% | +3.6% | -9.4% | — |
| Aug 11, 2023 | AMC | -4.80 | -4.20 | +12.5% | 8.00 | -5.4% | -1.8% | -8.3% | -3.6% | -5.9% | -5.0% | — |
| May 9, 2023 | AMC | -4.80 | -4.20 | +12.5% | 10.60 | +1.9% | -8.0% | +1.5% | -5.1% | +3.2% | -3.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30 | Chardan Capital | Maintains | Buy → Buy | — | $0.79 | $0.78 | -1.3% | -2.3% | +5.2% | +3.3% | +2.1% | +6.5% |
| Dec 9 | Chardan Capital | Maintains | Buy → Buy | — | $2.39 | $2.84 | +18.8% | -35.6% | -3.2% | -4.7% | -7.7% | -7.6% |
| Aug 8 | Chardan Capital | Maintains | Buy → Buy | — | $1.54 | $1.57 | +1.9% | +2.6% | -3.8% | -2.6% | +4.1% | -0.6% |
| Jun 12 | Chardan Capital | Maintains | Buy → Buy | — | $2.81 | $2.96 | +5.3% | +1.8% | -9.1% | +10.0% | -2.8% | -18.0% |
| May 2 | Chardan Capital | Maintains | Buy → Buy | — | $3.25 | $3.29 | +1.2% | +2.2% | -1.2% | +0.6% | +0.6% | -0.3% |
| Dec 4 | Chardan Capital | Maintains | Buy → Buy | — | $7.14 | $7.07 | -1.0% | -7.4% | -6.2% | -11.3% | +18.5% | -13.8% |
| Dec 2 | Chardan Capital | Maintains | Buy → Buy | — | $2.16 | $7.09 | +228.2% | +363.0% | -28.6% | -7.4% | -6.2% | -11.3% |
| Aug 15 | Chardan Capital | Maintains | Buy → Buy | — | $7.86 | $7.66 | -2.5% | -8.3% | -3.6% | -5.9% | -5.0% | +3.4% |
| May 11 | Chardan Capital | Maintains | Buy → Buy | — | $9.75 | $10.10 | +3.6% | +1.5% | -5.1% | +3.2% | -3.1% | +4.5% |
| Mar 24 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $12.50 | $12.80 | +2.4% | +0.8% | -1.6% | -5.6% | -0.9% | +0.0% |
| Mar 23 | Chardan Capital | Maintains | Buy → Buy | — | $12.20 | $12.00 | -1.6% | +2.5% | +0.8% | -1.6% | -5.6% | -0.9% |
| Jan 30 | Chardan Capital | Maintains | Buy → Buy | — | $17.83 | $18.30 | +2.6% | +1.5% | +1.3% | -1.3% | +2.8% | -4.3% |
| Jan 27 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $18.30 | $18.70 | +2.2% | -2.6% | +1.5% | +1.3% | -1.3% | +2.8% |
| Dec 16 | JP Morgan | Maintains | Neutral → Neutral | — | $15.20 | $15.30 | +0.7% | +0.7% | -5.2% | -3.4% | -0.7% | +0.0% |
| Oct 7 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $65.20 | $65.10 | -0.2% | -31.3% | -12.3% | -8.4% | -11.1% | +17.8% |
| Sep 29 | BofA Securities | Maintains | Buy → Buy | — | $14.00 | $16.40 | +17.1% | +50.7% | +2.8% | +15.2% | +105.6% | +2.7% |
| Sep 23 | Chardan Capital | Maintains | Buy → Buy | — | $14.00 | $14.20 | +1.4% | -5.0% | -7.5% | +3.3% | +10.2% | +50.7% |
No insider trades available.
8-K · 1.01
!! High
Senti Biosciences, Inc. -- 8-K 1.01: Material Agreement
Senti Biosciences agreed to merge with Celadon Partners SPV 35 Limited, representing a significant corporate restructuring that will affect shareholder ownership and company operations.
Jul 15
8-K · 1.01
!! High
Senti Biosciences, Inc. -- 8-K 1.01: Material Agreement
May 26
8-K · 8.01
!! High
Senti Biosciences, Inc. -- 8-K 8.01: Material Event / Announcement
May 14
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Senti Biosciences stockholders face a tax-neutral reorganization, preserving their share positions without immediate tax consequences, which could signal a strategic merger or restructuring that maintains investor equity value.
Apr 1
8-K
Unknown — 8-K Filing
SNTI's SENTI-202 positive clinical data validates its Gene Circuit platform, potentially de-risking the lead program and justifying continued investor confidence in the pipeline's commercial viability.
Mar 27
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
SNTI entered a $2.0 million material agreement with GeneFab, signaling potential revenue growth and strategic partnership expansion that could strengthen market position and investor confidence.
Mar 19
Institutional (13F) — Top 7
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 537,504 | $591K | New | Jun 2026 |
| 2 | Citadel Advisors Llc | 107,100 | $118K | New | Jun 2026 |
| 3 | Menlo Ventures Management, L.p. | 35,737 | $39K | New | Jun 2026 |
| 4 | Blackrock, Inc. | 4,004 | $4K | New | Jun 2026 |
| 5 | Sbi Securities Co., Ltd. | 334 | $367 | New | Jun 2026 |
| 6 | Virtu Financial Llc | 22,795 | $25 | New | Jun 2026 |
| 7 | Caitong International Asset Management Co., Ltd | 1 | $1 | New | Jun 2026 |
Mutual Funds / ETFs (N-PORT) — Top 2
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Total Market Index Fund | 19,991 | $19K | May 2026 |
| 2 | Fidelity Series Total Market Index Fund | 18,801 | $18K | May 2026 |
Valuation
Market Cap
$96.7M
Enterprise Value
$80.3M
P/E (TTM)
-0.22x
Forward P/E
—
PEG Ratio
0.05x
P/B
17.27x
P/S
2544.17x
P/FCF
-2.22x
EV/EBITDA
—
Shares Out
224.8M
Financials (TTM)
Revenue
$38K
Net Income
-$51.5M
EBITDA
-$47.8M
Free Cash Flow
-$43.6M
Op Cash Flow
-$43.4M
EPS Basic
$-2.73
EPS Diluted
$-1.92
EPS Forward
$-1.09
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$51.2M
Total Liab.
$45.6M
Total Equity
$5.6M
Cash
$16.4M
LT Debt
$0
Book Value/Sh
$0.02
Debt/Equity
5.17x
Current Ratio
1.67
Quick Ratio
1.67
Returns & Growth
ROE
-1099.3%
ROA
-119.9%
ROIC
-149.7%
Rev Growth YoY
+0.0%
EPS Growth YoY
+76.2%
Price Returns
2W
+31.9%
1M
-23.0%
3M
-55.5%
6M
-46.0%
12M
-70.5%
Technicals
52W High
$2.39
52W Low
$0.34
50d MA
$0.71
200d MA
$1.07
RSI (14)
59.10
ATR (14)
$0.04
Beta
2.12
Avg Volume
327K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$6.00
High
$6.00
Low
$6.00
Median
$6.00
Data updated apr 27, 2026 2:15am
· Source: financialmodelingprep.com